Azeem Latib

Dr. Azeem Latib

Department of Cardiology, Montefiore Medical Center, New York, NY, USA
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2014 in JAMA
Verified
Journal Article
Open access
PDF file
DDDanny Dvir
Danny Dvir
JWJohn G. Webb
John G. Webb
SBSabine Bleiziffer
Sabine Bleiziffer
MPMiralem Pasic
Miralem Pasic
RWRon Waksman
Ron Waksman
RKRan Kornowski
Ran Kornowski
Surgical aortic valve replacements increasingly use bioprosthesis implants rather than mechanical valves.1 Structural valve deterioration can result in leaflet degeneration and failure, as evidenced by valve stenosis, regurgitation, or a combination of both.2-4 Owing to a considerable shift toward bioprosthesis implantation, it is expected that patients will increasingly present with degenerated bioprostheses. Treatment of patients with failed bioprostheses is a clinical challenge. Although reoperation is considered the standard of care, these patients are frequently elderly, and repeat cardiac surgery carries significant morbidity and mortality risks.5,6

1 April 2013 in JACC
Verified
Journal Article
Closed access
GAGanesh Athappan
Ganesh Athappan
EPEshan Patvardhan
Eshan Patvardhan
ETE. Murat Tuzcu
E. Murat Tuzcu
LSLars Georg Svensson
Lars Georg Svensson
PLPedro A. Lemos
Pedro A. Lemos
SKSamir R. Kapadia
Samir R. Kapadia

16 July 2013 in Circulation
Verified
Journal Article
Closed access
MBMarco Barbanti
Marco Barbanti
TYTae-Hyun Yang
Tae-Hyun Yang
JCJosep Rodès Cabau
Josep Rodès Cabau
CTCorrado Tamburino
Corrado Tamburino
DWDavid A. Wood
David A. Wood
JLJonathon Leipsic
Jonathon Leipsic
Background—: Aortic root rupture is a major concern with balloon-expandable transcatheter aortic valve replacement (TAVR). We sought to identify predictors of aortic root rupture during balloon-expandable TAVR by using multidetector computed tomography. Methods and Results—: Thirty-one consecutive patients who experienced left ventricular outflow tract (LVOT)/annular/aortic contained/noncontained rupture during TAVR were collected from 16 centers. A caliper-matched sample of 31 consecutive patients without annular rupture, who underwent pre-TAVR multidetector computed tomography served as a control group. Multidetector computed tomography assessment included short- and long-axis diameters and cross-sectional area of the sinotubular junction, annulus, and LVOT, and the presence, location, and extent of calcification of the LVOT, as well. There were no significant differences between the 2 groups in any preoperative clinical and echocardiographic variables. Aortic root rupture was identified in 20 patients and periaortic hematoma in 11. Patients with root rupture had a higher degree of subannular/LVOT calcification quantified by the Agatston score (181.2±211.0 versus 22.5±37.6, P <0.001), and a higher frequency of ≥20% annular area oversizing (79.4% versus 29.0%, P <0.001) and balloon postdilatation (22.6% versus 0.0%, P =0.005). In conditional logistic regression analysis for the matched data, moderate/severe LVOT/subannular calcifications (odds ratio, 10.92; 95% confidence interval, 3.23–36.91; P <0.001) and prosthesis oversizing ≥20% (odds ratio, 8.38; 95% confidence interval, 2.67–26.33; P <0.001) were associated with aortic root contained/noncontained rupture. Conclusions—: This study demonstrates that LVOT calcification and aggressive annular area oversizing are associated with an increased risk of aortic root rupture during TAVR with balloon-expandable prostheses. Larger studies are warranted to confirm these findings.

1 May 2017 in JACC
Verified
Journal Article
Open access
SYSung-Han Yoon
Sung-Han Yoon
SBSabine Bleiziffer
Sabine Bleiziffer
OBOle De Backer
Ole De Backer
VDVictoria Delgado
Victoria Delgado
TATakahide Arai
Takahide Arai
RMRaj Makkar
Raj Makkar
Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid aortic valve stenosis (AS). This study sought to compare the procedural and clinical outcomes in patients with bicuspid versus tricuspid AS from the Bicuspid AS TAVR multicenter registry. Outcomes of 561 patients with bicuspid AS and 4,546 patients with tricuspid AS were compared after propensity score matching, assembling 546 pairs of patients with similar baseline characteristics. Procedural and clinical outcomes were recorded according to Valve Academic Research Consortium-2 criteria. Compared with patients with tricuspid AS, patients with bicuspid AS had more frequent conversion to surgery (2.0% vs. 0.2%; p = 0.006) and a significantly lower device success rate (85.3% vs. 91.4%; p = 0.002). Early-generation devices were implanted in 320 patients with bicuspid and 321 patients with tricuspid AS, whereas new-generation devices were implanted in 226 and 225 patients with bicuspid and tricuspid AS, respectively. Within the group receiving early-generation devices, bicuspid AS had more frequent aortic root injury (4.5% vs. 0.0%; p = 0.015) when receiving the balloon-expanding device, and moderate-to-severe paravalvular leak (19.4% vs. 10.5%; p = 0.02) when receiving the self-expanding device. Among patients with new-generation devices, however, procedural results were comparable across different prostheses. The cumulative all-cause mortality rates at 2 years were comparable between bicuspid and tricuspid AS (17.2% vs. 19.4%; p = 0.28). Compared with tricuspid AS, TAVR in bicuspid AS was associated with a similar prognosis, but lower device success rate. Procedural differences were observed in patients treated with the early-generation devices, whereas no differences were observed with the new-generation devices.

1 December 2019 in JACC
Verified
Journal Article
Closed access
MTMaurizio Taramasso
Maurizio Taramasso
GBGiovanni Benfari
Giovanni Benfari
PBPieter van der Bijl
Pieter van der Bijl
HAHannes Alessandrini
Hannes Alessandrini
AAAdrian Attinger-Toller
Adrian Attinger-Toller
FMFrancesco Maisano
Francesco Maisano

6 January 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
ACAntonio Colombo
Antonio Colombo
EBEzio Bramucci
Ezio Bramucci
SSSalvatore Saccà
Salvatore Saccà
RVRoberto Violini
Roberto Violini
CLCorrado Lettieri
Corrado Lettieri
FAFlavio Airoldi
Flavio Airoldi
Background— Sirolimus-eluting stents have been reported to be effective in the treatment of coronary bifurcations. Still, it has not been fully clarified which strategy would provide the best results with true bifurcation lesions. Methods and Results— The CACTUS trial (Coronary bifurcations: Application of the Crushing Technique Using Sirolimus-eluting stents) is a prospective, randomized, multicenter study comparing 2 different techniques of stenting, with mandatory final kissing-balloon inflation, in true bifurcations: (1) elective “crush” stenting and (2) stenting of only the main branch, with provisional side-branch T-stenting. From August 2004 to June 2007, 350 patients were enrolled in 12 European centers. The primary angiographic end point was the in-segment restenosis rate, and the primary clinical end point was the occurrence of major adverse cardiac events (cardiac death, myocardial infarction, or target-vessel revascularization) at 6 months. At 6 months, angiographic restenosis rates were not different between the crush group (4.6% and 13.2% in the main branch and side branch, respectively) and the provisional stenting group (6.7% and 14.7% in the main branch and side branch, respectively; P =NS). Additional stenting on the side branch in the provisional stenting group was required in 31% of lesions. Rates of major adverse cardiac events were also similar in the 2 groups (15.8% in the crush group versus 15% in the provisional stenting group, P =NS). Conclusions— In most bifurcations with a significant stenosis in both branches, a provisional strategy of stenting the main branch only is effective, with the need to implant a second stent on the side branch occurring in approximately one third of cases. The implantation of 2 stents does not appear to be associated with a higher incidence of adverse events at 6 months.